Genscript Biotech (HKG:1548) expects an increase in net profit in 2024, compared with the corresponding period of the previous year, according to a Sunday filing with the Hong Kong Bourse.
The company attributed the increased net profit to a one-time, tax-free unrealized gain of $3.2 billion from Legend Biotech's deconsolidation and future revenue from Probio's sublicensing, despite a $124 million fair value loss.
The life science research business plans to publish its annual results by the end of March.
The company's shares were down over 2% in the recent trading.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。